Læknaneminn - 01.04.1997, Side 135

The drug-AIDS hypothesis
168. Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L,
Baseler M, Massari F, Fox CH, Salzman NP, Fauci A. The reservoir
for HIV-1 in human peripheral blood is a T cell that maintains
expression of CD4. Science 1989; 245: 305-308.
169. Duesberg P, Bialy H. Duesberg and the Right of Reply According
to Maddox - Nature, in AIDS: Infectious or Not?, P. Duesberg (eds.)
Kluwer, Dordrecht, 1995;
170. Ascher MS, Sheppard HW, Anderson RW, Krowka JF, Bremermann
HJ. Paradox remains. Nature 1995; 375: 196.
171. Lauritsen J. Poison by Prescription—The AZT Story. Asklepios
Press, New York, 1990.
172. Wyatt EA. Rushing to Judgement. Barron’s 1994; 23-27, August,
15.
173. Hall CT. AIDS advances boost drugmaker. San Francisco
Chronicle (San Francisco) 1996: E1-E2, August 1.
174. Day M. Hype, hope and HIV. New Scientist 1996; 151: 28-31.
175. Rasnick D. Inhibitors of HIV protease useless against AIDS because
HIV doesn’t cause AIDS. Reappraising AIDS 1996; 4: 1-4.
176. Altman L. Scientists display substantial gains in AIDS treatment.
New York Times (New York) 1996: 1A, July 11.
177. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P,
Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw
GM. Viral dynamics in human immunodeficiency virus type 1
infection. Nature 1995; 373: 117-122.
178. Wain-Hobson S. Virological mayhem. Nature 1995; 373: 102.
179. Duesberg PH, Schwartz JR. Latent viruses and mutated oncogenes:
no evidence for pathogenicity. Progress in Nucleic Acid Research
and Molecular Biology 1992; 43: 135-204.
180. Tanaka M. Abrams cautious on use of new AIDS drugs. Synapse
1996; 41: 1,5.
181. Continuum. Drugs Boost. Continuum 1996; 4: 3, July/August.
182. Selik RM, Buehler JW, Karon JM, Chamberland ME, Berkelman
RL. Impact of the 1987 revision of the case definition of acquired
immune deficiency syndrome in the United States. J AIDS 1990; 3:
73-82.
183. Darby SC, Ewart DW, Giangrande PLF, Dolin PJ, Spooner RJD,
Rizza CR, on behalf of the UK Haemophilia Centre Directors’
Organisation. Mortality before and after HIV infection in the com-
plete UK population of haemophiliacs (letter). Nature 1995; 377:
79-82.
184. The Lancet. Zidovudine for mother, fetus, and child: hope or poi-
son? Lancet 1994; 344: 207-209.
185. Cotton P. Trial Halted After Drug Cuts Maternal HIVTransmission
Rate By Two Thirds. JAMA 1994; 271: 807.
186. Gill PS, Harrington WJ, Kaplan MH, Ribeiro RC, Bennett JM,
Liebmann HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S,
et al. Treatment of adult T-cell leukemia-lymphoma with a combi-
nation of interferon alfa and zidovudine. NEJM 1995; 332: 1744-
1748.
187. Continuum. Clever drug or is it the marketing? Continuum 1995;
3: 2, November/December.
188. Potts M. Non-surgical abortion: who’s for methotrexate. Lancet
1995; 346: 655-656.
189. Bethell T. The Cure that Failed. National Review 1993; 33-36,
May 10.
190. Greenblatt RM, Hollander H, McMaster JR, Henke CJ.
Polypharmacy among patients attending an AIDS clinic: utilization
of prescribed, unorthodox, and investigational treatments. Journal
ofAcquired Immune Deficiency Syndromes 1991; 4: 136-143.
191. Kramer L. Checking in, my chart. POZ 1994; 92-93,
August/September.
192. Tuller D. Uncertain life after certain death. San Francisco
Chronicle (San Francisco) 1996: 1-5 zone 6, November 24.
193. Grubman S, Gross E, Lerner-Weiss N, Hernandez M, McSherry
GD, Hoyt LG, Boland M, Oleske JM. Older Children and
Adolescents Living with Perinatally Acquired Human
Immunodeficiency Virus Infection. Pediatrics 1995; 95: 657-663.
194. Merck Research Laboratories. The Merck Manual of Diagnosis and
Therapy. Merck & Co., Inc., Rahway, NJ, 1992.
195. Freiman JP, Helfert KE, Hamrell MR, Stein DS. Hepatomegaly
with severe steatosis in HlV-seropositive patients. AIDS 1993; 7:
379-385.
196. McLeod GX, Hammer SM. Zidovudine: Five Years Later. Annals
oflnternal Medicine 1992; 117: 487-501.
197. Parker WB, Cheng YC. Mitochondrial Toxicity of Antiviral
Nucleoside Analogs. The Journal of NIH Research 1994; 6: 57-61.
198. Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D,
Steinberg S, Wyviil KM, Raubitschek A, Katz D, Broder S.
Development of non-Hodgkin lymphoma in a cohort of patients
with severe human immunodeficiency virus (HIV) infection on
long-term antiretroviral therapy. Ann Intern Med 1990; 113: 276-
282.
199. Aboulker J-P, Swart AM. Preliminary analysis of the Concorde trial.
The Lancet 1993; 341: 889-890.
200. Kumar RM, Hughes PF, Khurranna A. Zidovudine Use in
Pregnancy: A Report on 104 Cases and the Occurence of Birth
Defects. Journal of Acquired Immune Deficiency Syndromes 1994;
7: 1034-1039.
201. Saah AJ, Hoover DR, Peng Y, Phair JP, Visscher B, Kingsley LA,
Schrager LK, for the Multicenter AIDS Cohort Study. Predictors for
failure of Pneumocystis carinii pneumonia prophylaxis. JAMA
1995; 273: 1197-1202.
202. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A,
Volberding PA, Testa MA. Evaluation of the quality of life associat-
ed with Zidovudine treatment in asymptomatic Human
Immunodeficiency Virus infection. N Engl J Med 1994; 330: 738-
743.
203. Poznansky MC, Coker R, Skinner C, Hill A, Bailey S, Whitaker L,
Renton A, Weber J. HIV positive patients first presenting with an
AIDS defining illness: characteristics and survival. British Medical
Journal 1995; 311: 156-158.
204. Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SV,
Rabkin CS, Yellin FJ, Rosenberg PS, Aledort LM. Risks of immun-
odeficiency, AIDS, and death related to purity of factor VIII con-
centrate. Lancet 1994; 344: 791-792.
205. Moye J, Rich KC, Kalish LA, Sheon AR, Diaz C, Cooper ER, Pitt J,
Handelsman E, for the Women and Infants Transmission Study
Group. Natural history of somatic growth in infants born to women
infected by human immunodeficiency virus. The Journal of
Pediatrics 1996; 128: 58-67.
206. Pennisi E, Cohen J. Eradicating HIV from a patient: not just a
dream? Science 1996; 272: 1884.
207. Douglas RGJ. Antimicrobial Agents, in The Pharmacological Basis
of Therapeutics, Alfred, Goodman, Gilman and et al. (eds.)
Pergamon Press, New York, 1990; 1182.
208. Jacobson MA, de Miranda P, Gordon SM, et al. Prolonged pancy-
topenia due to combined ganciclovir and zidovuduine therapy. J
Infect Dis 1988; 158: 489-490.
209. Fogelman I, Lim L, Bassett R, Volberding P, Fischl MA, Stanley K,
Cotton DJ, for the AIDS Clinical Trials Group. Prevalence and pat-
terns of use of concomitant medications among participants in three
multicenter human immunodeficiency virus type 1 clinical trials.
Journal of Acquired Immune Deficiency Syndromes 1994; 7: 1057-
1063.
210. Leland J. The end of AIDS? Newsweek 1996; 64-73, December 2.
211. Ottoboni A. Dose makes the poison. Van Nostrand & Reingold/
Int. Tompson Publishing, 1991.
212. Fenner F, McAuslan BR, Mims CA, Sambrook J, White DO. The
Biology of Animal Viruses. Academic Press, Inc., New York, 1974.
213. KriegerT, Caceres CA. Wall Street Journal 1985: October 24.
214. Mathur-Wagh U, Enlow RW, Spigland I, Winchester RJ, Sacks HS,
Rorat E, Yancovitz SR, Klein MJ, William DC, Mildwan D.
Longitudinal study of persistent generalized lymphadenopathy in
homosexual men: Relation to acquired immunodeficiency syn-
drome. Lancet 1984; i: 1033-1038.
215. Marmor M, Friedman-Kien AE, Laubenstein L, Byrum RD,
William DC, D’Onofrio S, Dubin N. Risk factors for Kaposi’s sar-
coma in homosexual men. Lancet 1982; i: 1083-1087.
216. Newell GR, Mansell PWA, Wilson MB, Lynch HK, Spitz MR,
Hersh EM. Risk factor analysis among men referred for possible
acquired immune deficiency syndrome. Preventive Med 1985; 14:
81-91.
217. Haverkos HW, Pinsky PF, Drotman DP, Bregman DJ. Disease man-
ifestation among homosexual men with acquired immunodeficiency
LÆKNANEMINN
133 1. tbl. 1997, 50. árg.